DRUG Stock Overview
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bright Minds Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.37 |
| 52 Week High | CA$8.58 |
| 52 Week Low | CA$1.29 |
| Beta | 1.53 |
| 1 Month Change | -7.43% |
| 3 Month Change | -47.31% |
| 1 Year Change | -59.10% |
| 3 Year Change | -95.14% |
| 5 Year Change | n/a |
| Change since IPO | -96.72% |
Recent News & Updates
Shareholder Returns
| DRUG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 5.4% | 3.5% | 2.5% |
| 1Y | -59.1% | -34.9% | 7.6% |
Return vs Industry: DRUG underperformed the Canadian Biotechs industry which returned -38.4% over the past year.
Return vs Market: DRUG underperformed the Canadian Market which returned 7.5% over the past year.
Price Volatility
| DRUG volatility | |
|---|---|
| DRUG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: DRUG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine DRUG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Ian McDonald | brightmindsbio.com |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety.
Bright Minds Biosciences Inc. Fundamentals Summary
| DRUG fundamental statistics | |
|---|---|
| Market cap | CA$6.12m |
| Earnings (TTM) | -CA$6.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs DRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRUG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$6.72m |
| Earnings | -CA$6.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DRUG perform over the long term?
See historical performance and comparison